Mass Torts

October 19, 2026

Hair Relaxer Lawsuit

Our lawyers are reviewing hair relaxer cancer lawsuits for women across the United States. These claims involve women who used chemical hair relaxers or hair straighteners for years and were later diagnosed with uterine cancer, including endometrial cancer, ovarian cancer, or serious uterine fibroids that led to a hysterectomy.

The federal hair relaxer litigation included 12,381 pending lawsuits as of October 1, 2026. The cases are moving through expert discovery and bellwether preparation in the Northern District of Illinois. This litigation has been going on for years, but there is still no global hair relaxer settlement or MDL payout program. That does not mean our lawyers are not bullish on these cases. We are. It is just moving slowly, which is how it goes sometimes in the MDL mass torts. We still expect a favorable global settlement when all is said and done.

The strongest cases generally involve frequent, long-term use followed by uterine or ovarian cancer, a clear product history, and substantial treatment or reproductive injury.

October 19, 2026

Camp Lejeune Lawsuit News and Updates

by Ronald V. Miller, Jr.

This page provides updates on Camp Lejeune lawsuits. Our lawyers are still working to give the latest update on the litigation, even though we are no longer taking new cases. Why? Because there is little information out there, and we are staying with victims, including those we do not represent, until the end.

We recently reopened the comments below on October 19 to give you a chance to share your thoughts.

Latest Camp Lejeune Lawsuit Updates for 2026

October 18, 2026

Tylenol Autism Lawsuit

by Ronald V. Miller, Jr.

Our lawyers stopped accepting new Tylenol autism and ADHD cases after Judge Denise Cote excluded the plaintiffs’ causation experts, a ruling that led to the dismissal of the federal lawsuits.

There is now real reason for renewed optimism. In July 2026, the Second Circuit overturned the judgments resulting from Judge Cote’s expert testimony rulings. The defendants then asked the appeals court to reconsider, and, as we discuss below, that request has now been denied.

But our firm has not yet resumed accepting new Tylenol autism or ADHD claims. The appeals court did not decide that Tylenol causes autism or ADHD, and important questions about the expert evidence still have to be addressed on remand. We will continue following the litigation and reassess our position as the next steps become clearer.

October 17, 2026

Social Media Addiction Lawsuit

by Ronald V. Miller, Jr.

This page is about social media addiction lawsuits and who is eligible to bring a claim. Our lawyers also provide the latest news on social media class action lawsuits (including the ongoing trial in California).

The problem that led to social media lawsuits is that millions of people, too many of whom are children, are addicted to social media platforms such as Facebook, Instagram, Snapchat, and others. For these vulnerable users, social media addiction can be very harmful and lead to things like eating disorders, depression, and, in some cases, suicide.

Now, these companies are facing a wave of new social media lawsuits alleging that they knowingly designed the algorithms of their platforms to lure young people into harmful addictions.

October 17, 2026

Olympus Scope Lawsuit

by Ronald V. Miller, Jr.

Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients at hospitals across the United States. At least 35 people died from these medical scopes.

What happened? These awful infections were caused by dangerous, drug-resistant bacteria that were extremely difficult to treat.

So you had patients who went to the hospital, often getting diagnostic or therapeutic procedures that they did not think would be a big deal, only to come out with infections that damaged organs, required months of intensive care, or, tragically, proved fatal.

October 16, 2026

Dupixent Lawsuit for T-Cell Lymphoma

by Ronald V. Miller, Jr.

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas.

On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, COPD, and a host of other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different and not one they could have expected.

October 16, 2026

Paraquat Lawsuit Settlement Amounts

by Ronald V. Miller, Jr.

Our lawyers handle Paraquat lawsuits in all 50 states. This page provides the latest news and updates on Paraquat lawsuits in both state and federal courts. We also give our perspective on where this litigation is heading and provide projected settlement payouts for a viable Paraquat lawsuit.

October 15, 2026

Bard PowerPort Lawsuit

by Ronald V. Miller, Jr.

Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona. After a long slog, these cases are now moving forward.

The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The most recent trial, Divelbliss v. C.R. Bard, led to a $40 million verdict. It involved an alleged fracture of a silicone Groshong catheter. Five bellwether trials are now expected to run through February 2027. So far, we are 1-1, with the third trial now getting underway. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases.

This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim.

October 15, 2026

Baby Food Autism Lawsuit

by Ronald V. Miller, Jr.

Our law firm is handling baby food autism lawsuits in all 50 states.

Several popular brands of baby food contain high levels of heavy metals such as mercury, arsenic, lead, and cadmium. These heavy metals are well-known neurotoxins. Thousands of children may have developed autism and other neurodevelopmental disorders due to toxic metals found in baby foods.

A growing number of parents are pursuing a toxic baby food lawsuit to hold manufacturers accountable for their children’s exposure to harmful contaminants. These baby food autism lawsuits allege the manufacturers knew about heavy metals in their products, and children developed autism from consuming them.

October 12, 2026

Breast Mesh Lawsuits and Internal Bra Complications

by Ronald V. Miller, Jr.

Breast mesh lawsuits allege that some manufacturers promoted or allowed their mesh products to become widely used in breast reconstruction, augmentation, and revision procedures despite the fact that FDA has not cleared or approved any surgical mesh product for use in breast surgery. The FDA has specifically stated that the safety and effectiveness of surgical mesh in breast surgery, including augmentation and reconstruction, has not been determined.

These internal bra lawsuits allege that manufacturers of products such as AlloDerm, GalaFLEX, Phasix, AlloMax, FlexHD, Strattice, and DuroSorb marketed their devices for breast reconstruction, augmentation, and revision surgeries even though those breast-specific applications had not been adequately studied or cleared by the FDA. Patients were not warned. Surgeons were not given enough information. So when complications developed, including infection, mesh failure, chronic pain, implant loss, breast deformity, and the need for additional surgery, many women had no reason to connect their injuries to the mesh product placed inside them.